Please use symbol entry at top right of page to search

US STOCKS-Wall Street jumps over 1% in choppy trading as yields dip

(For a Reuters live blog on U.S., UK and European stock markets, click or type LIVE/ in a news window.)

*

Apple (AAPL) down 2.83% on move to drop iPhone production boost

*

U.S. 10-yr Treasury yields ease from 12-year highs

*

Biogen soars on landmark Alzheimer's data

*

Indexes up: Dow 1.55%, S&P 1.65%, Nasdaq 1.57%

(Updates prices throughout, adds comments)

By Shreyashi Sanyal and Ankika Biswas

Sept 28 (Reuters) - U.S stock indexes jumped more than 1% in volatile trading on Wednesday as easing Treasury yields lifted rate-sensitive growth stocks, while losses in Apple Inc (AAPL) after it dropped plans to boost iPhone production hurt the technology sector.

Equity markets also got a boost from a Bank of England decision to restore financial stability by buying as many long-dated government bonds as needed. The move lifted British bond prices and pushed global benchmark yields lower.

The yield on the U.S. 10-year Treasury bill came off 12-year highs to hit the day's low of 3.751%, while Germany's 10-year government bond yield, the benchmark for the euro zone, fell after touching a 11-year high.

Investors also keenly listened to comments from Federal Reserve officials on the path of monetary policy, with Atlanta Fed President Raphael Bostic backing another 75 basis-point interest rate hike in November.

Much to the market's relief, Fed Chair Jerome Powell did not comment on monetary policy or the U.S. economic outlook on Wednesday.

Amid an aggressive push by the Fed to raise borrowing costs even at the risk of slowing down economic growth, Wall Street's main indexes remained in a bear market, with the S&P 500 recording its lowest close in almost two years on Tuesday.

"Can the move up in stock prices today be sustained for a period of time? Well, maybe a couple of days, but I don't think we can use the expression 'out of the woods' with the concerns about the economy getting deeper," said Hugh Johnson, chief economist of Hugh Johnson Economics in Albany, New York.

Meanwhile, shares of the world's most valuable public company lost 2.83% after Bloomberg reported that Apple (AAPL) told suppliers to curtail efforts to increase assembly of its iPhone 14 products by as many as 6 million units in the second half of this year.

"Apple's (AAPL) announcement...does play into that notion that we're already in a situation where it's harder for companies to start to see their profit continue to hold at previous levels during the recovery from the pandemic," said Daniela Hathorn, market analyst, Capital.com.

Among the 11 S&P 500 sector indexes, technology was the sole decliner, down 0.5% due to Apple's (AAPL) drag. Leading the gains were communication services, healthcare and energy, up between 2% and 2.5%.

At 12:19 p.m. ET, the Dow Jones Industrial Average was up 452.74 points, or 1.55%, at 29,587.73, the S&P 500 was up 60.32 points, or 1.65%, at 3,707.61, and the Nasdaq Composite was up 169.50 points, or 1.57%, at 10,999.00.

Biogen shares surged 37.47% after its Alzheimer's drug, developed with Japanese partner Eisai (ESALF), succeeded in slowing cognitive decline.

Eli Lilly & Co, which is also developing an Alzheimer's drug, rose 8.17% and was among the biggest boosts to the S&P 500 index.

Advancing issues outnumbered decliners by a 6.43-to-1 ratio on the NYSE and by a 4.02-to-1 ratio on the Nasdaq.

The S&P index recorded one new 52-week high and 30 new lows, while the Nasdaq recorded 21 new highs and 192 new lows. (Reporting by Shreyashi Sanyal, Susan Mathew and Ankika Biswas in Bengaluru; Editing by Vinay Dwivedi and Arun Koyyur)

Copyright © Reuters 2008. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

News, commentary and research reports are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.